Molecular subtypes and clinicopathological features of breast cancer in Mexican women.

Autor:	Martínez-Silva MG; Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente 'Lic. Ignacio García Téllez', Hospital de Especialidades, Servicio de Anatomía Patológica. Guadalajara, Jalisco., García-Chagollán M; Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Ciencias Biomédicas, Departamento de Fisiología. Guadalajara, Jalisco., Aguilar-Lemarroy A; Instituto Mexicano del Seguro Social, Centro de Investigación Biomédica de Occidente, División de Inmunología. Guadalajara, Jalisco., Hernández-Gutiérrez R; Consejo Nacional de Ciencia y Tecnología, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A.C. (CIATEJ), Unidad de Biotecnología Medica y Farmacéutica. Guadalajara, Jalisco., Leal-Herrera YA; Instituto Mexicano del Seguro Social, Centro Institucional de Capacitación y Registro de Cáncer (CICyRC). Mérida, Yucatán., Ruiz-Tachiquín ME; Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Pediatría 'Dr. Silvestre Frenk Freund', Unidad de Investigación Médica en Genética Humana. Ciudad de México., González-López S; Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Hospital de Especialidades, Laboratorio Regional de Citología Exfoliativa. Guadalajara, Jalisco. México., Jave-Suárez LF; Instituto Mexicano del Seguro Social, Centro de Investigación Biomédica de Occidente, División de Inmunología. Guadalajara, Jalisco.
Jazyk:	Spanish; Castilian
Zdroj:	Revista medica del Instituto Mexicano del Seguro Social [Rev Med Inst Mex Seguro Soc] 2020 Apr 27; Vol. 58 (Supl 1), pp. S21-S31.
DOI:	10.24875/RMIMSS.M20000112
Abstrakt:	Background: Breast cancer is a multifactorial and heterogeneous disease with distinct molecular features and histopathologic subtypes involving different therapeutic responses and clinical outcomes. Classification of breast cancer in molecular subtypes has made possible an approach to develop therapeutic strategies in order to have a better understanding of the breast cancer development. Due to the heterogeneity of the disease, there are still features to be elucidated in the behavior, etiology and clinical outcomes of each molecular subtype in breast cancer. Methods: Variables measured in 1,695 cases of invasive breast carcinoma were age, histopathological diagnosis, histopathological grade, expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), cell proliferation marker (Ki67) and basal cytokeratins (CK 5/6). P values were obtained using Chi square test and hazard ratios were calculated with 95% confidence intervals. Results: An increase of aggressive molecular subtypes of breast cancer was observed. The mean age of incidence of breast cancer patients is decreasing, and breast cancer Patients younger than 40-years-old showed higher risk to exhibit Triple negative and Basal-like tumors. Conclusions: The mean age for this pathology is decreasing in our population and there is predominance in the differential occurrence of etiologically distinct entities of breast cancer affecting to the young women. (Copyright: © 2020 Revista Medica del Instituto Mexicano del Seguro Social.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu